You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

 

Online download statistics by month:

Online download statistics by month: January 2023 to March 2024

AbstractFullPdf
Jan 2023674683145
Feb 2023341355111
Mar 202318820162
Apr 202314614755
May 202312512641
Jun 202311811844
Jul 202310610637
Aug 202315915836
Sep 202311311345
Oct 2023656517
Nov 2023878721
Dec 2023848633
Jan 2024565834
Feb 2024474720
Mar 2024595952
Total23682409753